Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Protein expression of PD-L1 and clinico-pathological data in a cohort of 53 patients with resectable non small cell lung cancer (NSCLC). Concordance between clones (22C3 and 28-8) and observers. Correlation and prognostic value of clinico-pathological data].
Esteban-Rodríguez I, Ruiz Bravo-Burguillos E, Rosas R, Losantos I, Rodríguez-Antolín C, de Castro J. Esteban-Rodríguez I, et al. Rev Esp Patol. 2020 Jan-Mar;53(1):10-18. doi: 10.1016/j.patol.2019.04.003. Epub 2019 Jul 2. Rev Esp Patol. 2020. PMID: 31932004 Spanish.
DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through MAFG Overexpression in Cancer Cells.
Vera O, Jimenez J, Pernia O, Rodriguez-Antolin C, Rodriguez C, Sanchez Cabo F, Soto J, Rosas R, Lopez-Magallon S, Esteban Rodriguez I, Dopazo A, Rojo F, Belda C, Alvarez R, Valentin J, Benitez J, Perona R, De Castro J, Ibanez de Caceres I. Vera O, et al. Theranostics. 2017 Sep 22;7(17):4118-4134. doi: 10.7150/thno.20112. eCollection 2017. Theranostics. 2017. PMID: 29158814 Free PMC article.
MAFG is a potential therapeutic target to restore chemosensitivity in cisplatin-resistant cancer cells by increasing reactive oxygen species.
Vera-Puente O, Rodriguez-Antolin C, Salgado-Figueroa A, Michalska P, Pernia O, Reid BM, Rosas R, Garcia-Guede A, SacristÁn S, Jimenez J, Esteban-Rodriguez I, Martin ME, Sellers TA, León R, Gonzalez VM, De Castro J, Ibanez de Caceres I. Vera-Puente O, et al. Transl Res. 2018 Oct;200:1-17. doi: 10.1016/j.trsl.2018.06.005. Epub 2018 Jun 30. Transl Res. 2018. PMID: 30053382 Free PMC article.
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study.
Conde E, Hernandez S, Martinez R, Angulo B, De Castro J, Collazo-Lorduy A, Jimenez B, Muriel A, Mate JL, Moran T, Aranda I, Massuti B, Rojo F, Domine M, Sansano I, Garcia F, Felip E, Mancheño N, Juan O, Sanz J, Gonzalez-Larriba JL, Atienza-Cuevas L, Arriola-Arellano E, Abdulkader I, Garcia-Gonzalez J, Camacho C, Rodriguez-Abreu D, Teixido C, Reguart N, Gonzalez-Piñeiro A, Lazaro-Quintela M, Lozano MD, Gurpide A, Gomez-Roman J, Lopez-Brea M, Pijuan L, Salido M, Arriola E, Company A, Insa A, Esteban-Rodriguez I, Saiz M, Azkona E, Alvarez R, Artal A, Plaza ML, Aguiar D, Enguita AB, Benito A, Paz-Ares L, Garrido P, Lopez-Rios F. Conde E, et al. J Thorac Oncol. 2019 Dec;14(12):2120-2132. doi: 10.1016/j.jtho.2019.07.005. Epub 2019 Jul 23. J Thorac Oncol. 2019. PMID: 31349061 Free article.
A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens.
Bubendorf L, Conde E, Cappuzzo F, Langfort R, Schildhaus HU, Votruba J, Concha-López Á, Esteban-Rodriguez I, Feng J, Devenport J, Boyiddle C, Morris S, Trunzer K, Kerr KM. Bubendorf L, et al. Cancer Cytopathol. 2020 Dec;128(12):928-938. doi: 10.1002/cncy.22324. Epub 2020 Jul 28. Cancer Cytopathol. 2020. PMID: 32721105 Free PMC article.
Novel SLC12A2-ROS1 Fusion in Non-Small Cell Lung Cancer with a Significant Response to Crizotinib: The Importance of Choosing the Appropriate Next-Generation Sequencing Assay.
Rodríguez-Antolín C, Rosas-Alonso R, Cruz P, Higuera O, Sánchez-Cabrero D, Esteban-Rodríguez I, Peláez-García A, Fernández Montaño VE, Rodríguez-Jiménez C, Ibáñez de Cáceres I, de Castro J. Rodríguez-Antolín C, et al. Oncologist. 2021 Jun;26(6):e908-e912. doi: 10.1002/onco.13745. Epub 2021 Mar 26. Oncologist. 2021. PMID: 33682977 Free PMC article.
RET Fusion Testing in Patients With NSCLC: The RETING Study.
Conde E, Hernandez S, Rodriguez Carrillo JL, Martinez R, Alonso M, Curto D, Jimenez B, Caminoa A, Benito A, Garrido P, Clave S, Arriola E, Esteban-Rodriguez I, De Castro J, Sansano I, Felip E, Rojo F, Dómine M, Abdulkader I, Garcia-Gonzalez J, Teixido C, Reguart N, Compañ D, Insa A, Mancheño N, Palanca S, Juan-Vidal O, Baixeras N, Nadal E, Cebollero M, Calles A, Martin P, Salas C, Provencio M, Aranda I, Massuti B, Lopez-Vilaro L, Majem M, Paz-Ares L, Lopez-Rios F. Conde E, et al. Among authors: esteban rodriguez i. JTO Clin Res Rep. 2024 Feb 20;5(4):100653. doi: 10.1016/j.jtocrr.2024.100653. eCollection 2024 Apr. JTO Clin Res Rep. 2024. PMID: 38525319 Free PMC article.
Evaluation of the clinical use of MGMT methylation in extracellular vesicle-based liquid biopsy as a tool for glioblastoma patient management.
Rosas-Alonso R, Colmenarejo-Fernández J, Pernía O, Burdiel M, Rodríguez-Antolín C, Losantos-García I, Rubio T, Moreno-Velasco R, Esteban-Rodríguez I, Martínez-Marín V, Yubero P, Costa-Fraga N, Díaz-Lagares A, López-López R, Díaz-Martin E, García JF, Sánchez CV, Gandía-González ML, Moreno-Bueno G, de Castro J, de Cáceres II. Rosas-Alonso R, et al. Among authors: esteban rodriguez i. Sci Rep. 2024 May 18;14(1):11398. doi: 10.1038/s41598-024-62061-8. Sci Rep. 2024. PMID: 38762534 Free PMC article.
25 results